<https://rdf.molmedb.upol.cz/reference/ref542> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM16707>,
		<https://rdf.molmedb.upol.cz/transporter/target2>;
	<http://purl.org/ontology/bibo/pmid> "11901224"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/ontology/bibo/doi> "10.1124/mol.61.4.853"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/bibliographicCitation> "Briz O, Serrano MA, Rebollo N, Hagenbuch B, Meier PJ, Koepsell H, Marin JJ.: Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol Pharmacol, Volume 61 (4), 2002"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/transporter/target41> .
<https://rdf.molmedb.upol.cz/transporter/tra32501> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref542> .
<https://rdf.molmedb.upol.cz/transporter/tra32502> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref542> .